Health Condition 1: L209- Atopic dermatitis, unspecified Health Condition 2: L209- Atopic dermatitis, unspecified
Conditions
Interventions
Intervention1: Vitamin D3: Single dose Vitamin D3 will be given to children with atopic dermatitis
Control Intervention1: Not applicable: Not applicable
Sponsors
Intramural funds Institute Ethics Committee
Eligibility
Inclusion criteria
Inclusion criteria: All Children with atopic dermatitis from the age group of 1 year till 14 years attending JIPMER Pediatrics and Dermatology OPD will be recruited and single oral dose Vitamin D3 ( 1,20,000 IU) will be given at enrolment.
Exclusion criteria
Exclusion criteria: 1) Children with chronic underlying disease on immunosuppressive therapy (Neurological/cardiac/metabolic/respiratory/gastrointestinal) 2) Children with known or suspected immunodeficiency. 3) Children on prolonged antibiotic therapy and Anti tuberculous therapy. 4) Children who are a part of other studies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| EVALUATION OF CLINICAL SEVERITY OF ATOPIC DERMATITIS AND DECREASE IN SCORAD LEVELS OVER A P FALL IN IgE ANTIBODY TITRES FALL IN ABSOLUTE EOSINOPHIL COUNTSTimepoint: OUTCOMES WILL BE ASSESSED AT THE END OF 4 MONTHS, AFTER GIVING SINGLE DOSE VITAMIN D | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) To assess the change in serum 25(OH) D levels after single oral dose ( 1,20,000 IU ) Vitamin D3 supplementation. 2) To assess the change in absolute eosinophil counts and IgE antibody titres after Vitamin D supplementation. 3) To assess the reduction in the number of exacerbations. Timepoint: 4 months | — |
Countries
India
Contacts
Public ContactDhayalini RK
Jawaharlal Institute Of Postgraduate Medical Education and Research
Outcome results
None listed